New Hampshire Trust’s Biogen BIIB Stock Holding History

New Hampshire Trust’s Portfolio BIIB Stock Details BIIB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-80	Closed	-$22.2K	–	188
2023 Q1	$22.2K	Hold	80	–	–	0.01%	303
2022 Q4	$22.2K	Buy	+80	New	+$22.6K	0.01%	306

Other funds holding BIIB

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

New Hampshire Trust's BIIB Position: Q2 2023 in Review

New Hampshire Trust sold out of Biogen (BIIB) in Q2 2023, closing a stake of 80 shares — an estimated $22.2K sold.

New Hampshire Trust first reported a position in BIIB in Q4 2022 and held it in 2 quarters. The position peaked at $22.2K in Q1 2023. 1,008 funds tracked by Wall St. Rank hold BIIB as of Q2 2023.

New Hampshire Trust reported no remaining Biogen position as of Q2 2023 after selling out during the quarter.
New Hampshire Trust sold 80 Biogen shares in Q2 2023, an estimated $22.2K.
New Hampshire Trust first reported a position in Biogen in Q4 2022 and held it in 2 quarters.
New Hampshire Trust's Biogen position peaked at $22.2K in Q1 2023.
1,008 funds tracked by Wall St. Rank held Biogen as of Q2 2023.

Based on New Hampshire Trust's 13F filing for Q2 2023, filed 11 Jul 2023.